April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Immunoperoxidase Staining For c-MET In Uveal Melanoma And Metastases
Author Affiliations & Notes
  • Lynn Schoenfield
    Anatomic Pathology, Cleveland Clinic, Cleveland, Ohio
  • Paula Carver
    Anatomic Pathology, Cleveland Clinic, Cleveland, Ohio
  • Ray Tubbs
    Anatomic Pathology, Cleveland Clinic, Cleveland, Ohio
  • Charles Biscotti
    Anatomic Pathology, Cleveland Clinic, Cleveland, Ohio
  • Arun D. Singh
    Cole Eye Institute, Cleveland, Ohio
  • Footnotes
    Commercial Relationships  Lynn Schoenfield, None; Paula Carver, None; Ray Tubbs, None; Charles Biscotti, None; Arun D. Singh, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1444. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lynn Schoenfield, Paula Carver, Ray Tubbs, Charles Biscotti, Arun D. Singh; Immunoperoxidase Staining For c-MET In Uveal Melanoma And Metastases. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1444.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : This study was undertaken to get further experience with immunoperoxidase staining of c-MET in uveal melanomas as well as in liver metastases. MET is a proto-oncogene which has been found to be deregulated in several malignancies, including carcinomas, sarcomas, hematologic malignancies, and glioblastoma. The most common genetic alteration is gene amplification leading to over-expression of MET. Evaluation of tumor expression may prove helpful as treatments aimed at modulating this gene are currently under investigation.

Methods: : 21 enucleated eyes for uveal melanoma were immunostained for c-MET. Liver (3 cases) and bone metastases (1 case) were also examined. Immunohistochemistry on FFPE tissue was performed with antigen retrieval on a Discovery XT automated stainer (Ventana, Tuscon, AZ). The primary c-MET (ab51067) antibody (rabbit monoclonal, Abcam, Cambridge, MA) was followed by a secondary antibody (UltraMap anti-Rb AP; Ventana) and ChromoMap Red (Ventana) was used for detection. Cells were then counterstained with hematoxylin and visualized by light microscopy. Staining was scored as follows: 0, no staining, 1, <10% cells, 2, 10-50% cells, and 3, >50% cells staining. The results were correlated with FISH results for monosomy 3 and clinical follow-up where available.

Results: : The enucleations were from 11 men and 10 women aged 40-86 (mean 65 yrs). FISH for monosomy 3 was done in 16 patients, and follow-up ranged from 1 month to 5 years. There were10 choroidal and 11 cilichoroidal melanomas. At the end of this study 6 patients had died (5 with known hepatic metastases, monosomy 3 and positive immunostaining for c-MET (1+ to 3+). The fifth case was monosomy 3 but negative for c-MET. Two cases were negative for c-MET, 1 with disomy 3 and the other with no FISH available; both patients are alive at 3 yrs. and 3 mo. respectively. The remaining 13 cases showed positive staining ranging from 1+ to 3+, which was often focal, the significance of which is unclear. One patient with 3+ staining is known to have liver metastasis; follow-up ranges from 1 mo to 4 years in this group. The 3 liver metastases studied showed positive staining, as did the bone (vertebral body) metastasis.

Conclusions: : While positive staining was found in 5 of 6 cases of death due to liver metastasis and 1 case of bone metastases, the findings are at this time inconclusive, due to insufficient time for follow-up. Further study is warranted, including evaluating the possible stratification of patients based on intensity of positive staining and locality within the tumor, which might reveal differences in tumor clones.

Keywords: melanoma • pathology techniques • uvea 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.